Clinical and treatment characteristics of all 98 sites of relapsed, refractory MCL treated with consolidative LDRT and associations with CR
| Variable . | No. of sites (%) . | CR, univariate . | CR, multivariable . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P* . | HR (95% CI) . | P* . | ||
| Site | |||||
| Soft tissue | 63 (64) | 1.80 (1.12-2.90) | .015 | 1.79 (1.11-2.89) | .018 |
| Non–soft tissue | |||||
| Nodal | 22 (22) | ||||
| GI | 7 (7) | ||||
| Orbit | 3 (3) | ||||
| Mucosal | 2 (2) | ||||
| Bone | 1 (1) | ||||
| No. of fractions | |||||
| 2, ×2 Gy | 72 (73) | 1.17 (0.68-2.02) | .566 | ||
| 1, ×4 Gy | 26 (27) | ||||
| RT modality | |||||
| Photons | 65 (66) | 0.68 (0.43-1.09) | .109 | ||
| Nonphotons | |||||
| Electrons | 32 (33) | ||||
| Orthovoltage | 1 (1) | ||||
| Diagnosis to LDRT | |||||
| ≥36 mo | 36 (37) | 0.73 (0.46-1.18) | .201 | ||
| <36 mo | 62 (63) | ||||
| Lesion size | |||||
| ≥3 cm | 47 (48) | 0.76 (0.48–1.21) | .245 | 0.69 (0.43-1.10) | .120 |
| <3 cm | 51 (52) | ||||
| Histology | |||||
| Blastoid | 27 (28) | 0.78 (0.45-1.35) | .374 | ||
| Nonblastoid | 71 (72) | ||||
| Chemorefractory | |||||
| Yes, to ongoing | 74 (76) | 1.41 (0.86-2.32) | .175 | 1.40 (0.84-2.32) | .194 |
| No, to ongoing | 24 (24) | ||||
| Ibrutinib-refractory | |||||
| Yes | 80 (82) | 1.10 (0.65-1.88) | .716 | ||
| No | 18 (18) | ||||
| Prior chemo | |||||
| >5 courses | 33 (34) | 0.97 (0.61-1.55) | .906 | ||
| ≤5 courses | 65 (66) | ||||
| Prior SCT | |||||
| Yes | 42 (43) | 0.92 (0.58-1.44) | .706 | ||
| No | 56 (57) | ||||
| Concurrent chemo | |||||
| Yes | 74 (76) | 1.26 (0.75-2.11) | .379 | ||
| No | 24 (24) | ||||
| Post-LDRT chemo | |||||
| Yes | 79 (81) | 0.99 (0.58-1.68) | .963 | ||
| No | 19 (19) | ||||
| Variable . | No. of sites (%) . | CR, univariate . | CR, multivariable . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P* . | HR (95% CI) . | P* . | ||
| Site | |||||
| Soft tissue | 63 (64) | 1.80 (1.12-2.90) | .015 | 1.79 (1.11-2.89) | .018 |
| Non–soft tissue | |||||
| Nodal | 22 (22) | ||||
| GI | 7 (7) | ||||
| Orbit | 3 (3) | ||||
| Mucosal | 2 (2) | ||||
| Bone | 1 (1) | ||||
| No. of fractions | |||||
| 2, ×2 Gy | 72 (73) | 1.17 (0.68-2.02) | .566 | ||
| 1, ×4 Gy | 26 (27) | ||||
| RT modality | |||||
| Photons | 65 (66) | 0.68 (0.43-1.09) | .109 | ||
| Nonphotons | |||||
| Electrons | 32 (33) | ||||
| Orthovoltage | 1 (1) | ||||
| Diagnosis to LDRT | |||||
| ≥36 mo | 36 (37) | 0.73 (0.46-1.18) | .201 | ||
| <36 mo | 62 (63) | ||||
| Lesion size | |||||
| ≥3 cm | 47 (48) | 0.76 (0.48–1.21) | .245 | 0.69 (0.43-1.10) | .120 |
| <3 cm | 51 (52) | ||||
| Histology | |||||
| Blastoid | 27 (28) | 0.78 (0.45-1.35) | .374 | ||
| Nonblastoid | 71 (72) | ||||
| Chemorefractory | |||||
| Yes, to ongoing | 74 (76) | 1.41 (0.86-2.32) | .175 | 1.40 (0.84-2.32) | .194 |
| No, to ongoing | 24 (24) | ||||
| Ibrutinib-refractory | |||||
| Yes | 80 (82) | 1.10 (0.65-1.88) | .716 | ||
| No | 18 (18) | ||||
| Prior chemo | |||||
| >5 courses | 33 (34) | 0.97 (0.61-1.55) | .906 | ||
| ≤5 courses | 65 (66) | ||||
| Prior SCT | |||||
| Yes | 42 (43) | 0.92 (0.58-1.44) | .706 | ||
| No | 56 (57) | ||||
| Concurrent chemo | |||||
| Yes | 74 (76) | 1.26 (0.75-2.11) | .379 | ||
| No | 24 (24) | ||||
| Post-LDRT chemo | |||||
| Yes | 79 (81) | 0.99 (0.58-1.68) | .963 | ||
| No | 19 (19) | ||||
chemo, chemotherapy; CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; SCT, stem cell transplantation.
Cox proportional hazards for univariate and multivariable analyses of associations with outcomes.